American Journal of Epidemiology Advance Access originally published online on May 30, 2008
American Journal of Epidemiology 2008 168(3):329-335; doi:10.1093/aje/kwn135
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PRACTICE OF EPIDEMIOLOGY |
Immeasurable Time Bias in Observational Studies of Drug Effects on Mortality
1 McGill Pharmacoepidemiology Research Unit, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
2 Departments of Epidemiology and Biostatistics and of Medicine, McGill University, Montreal, Quebec, Canada
Correspondence to Dr. Samy Suissa, McGill Pharmacoepidemiology Research Unit, Royal Victoria Hospital, 687 Pine Avenue West, Ross 4.29, Montreal, Québec, Canada H3A 1A1 (e-mail: samy.suissa{at}mcgill.ca).
Received for publication June 18, 2007. Accepted for publication April 22, 2008.
Observational studies suggesting that some drugs are effective at reducing mortality may have been subject to "immeasurable time bias" arising from the unidentified presence of hospitalizations when defining drug exposure with computerized health databases. The author illustrates the bias using a case-control study of 1,313 deaths and 1,313 controls selected from a cohort of 2,049 patients with chronic obstructive pulmonary disease from Saskatchewan, Canada, identified from 1990 and followed up through 1999. Different approaches were used to estimate the rate ratio of death associated with inhaled corticosteroid exposure, defined by a prescription dispensed in the 30-day period prior to the index date. More cases had been hospitalized during the 30-day exposure period (72%) than controls (26%), with lower durations of stay for cases who received an inhaled corticosteroid prescription (9.9 vs.16.2 days), thus introducing variations in measurable exposure times. The raw analysis that did not consider hospitalization found a rate ratio of 0.60 (95% confidence interval (CI): 0.50, 0.73). Alternatively, analyses accounting for variations in measurable times resulted in a rate ratio of 0.93 (95% CI: 0.76, 1.14) when weighted by measurable time, while use of the Kaplan-Meier estimator of the 30-day cumulative incidence of exposure found a rate ratio of 1.35 (95% CI: 1.14, 1.60). In conclusion, immeasurable time bias may be present in several observational database studies suggesting that certain drugs are effective at reducing mortality.
bias (epidemiology); case-control studies; cohort studies; databases as topic; drug therapy; misclassification; treatment outcome
Abbreviations: CI, confidence interval; HR, hazard ratio
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. B. Filion, V. Schneider-Lindner, I. Karp, L. E. Levesque, J. M. Brophy, and S. Suissa Continuation of Statin Treatment and Mortality: A Note of Caution on Excessive Benefits Arch Intern Med, June 8, 2009; 169(11): 1080 - 1080. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa and P. Ernst How Much Did Biases in the Study of Chronic Obstructive Pulmonary Disease Medications and Mortality Affect the Outcome? Ann Intern Med, March 17, 2009; 150(6): 425 - 426. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa Statistical methods in pharmacoepidemiology: advances and challenges Statistical Methods in Medical Research, February 1, 2009; 18(1): 3 - 6. [PDF]
|
|